As single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older: Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1 of the SmPC), Or: Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

Medicine details

Medicine name:
fingolimod (Gilenya)
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Submission type
Advice due date:
10 June 2019
SMC meeting date:
02 April 2019
Patient group submission deadline: